Publications

Marmé F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, García-Sáenz JA, Kelly CM, Reimer T, Valota O, Toi M, Rugo HS, Gnant M, Makris A, Bassy M, Zhang Z, Furlanetto J, Nekljudova V, Loibl S. Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. ESMO open. 2024. PMID: 38838498

Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, Kelley RK, Behr SC, Flavell RR, Lawhn-Heath C, Melisko M, Rugo HS, Wang V, Yom SS, Ha P, Jiang F, Hope TA. 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2024. PMID: 38697672

Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Brégeault MF, Macé S, Berthou C, Bregman D, Klippel Z, Orlowski RZ, IMROZ Study Group. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine. 2024. PMID: 38832972

Subramanian A, Zhang M, Sharifi M, Moreno-Rodriguez T, Feng E, Rydzewski NR, Shrestha R, Zhu X, Zhao SG, Aggarwal R, Small EJ, Ding CC, Quigley DA, Sjöström M. A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy. bioRxiv : the preprint server for biology. 2024. PMID: 38895460

Gorrilla AA, Kaye JT, Pavlik J, Bonniot C, Vijayaraghavan M, Conner KL, Morris CD. A Call for Health Equity in Tobacco Control and Treatment for the Justice-Involved Population. American journal of preventive medicine. 2024. PMID: 38838793

Chloe Evelyn Atreya, Ivan C. Leung, Maria T. Chao, Ariana Thompson-Lastad, Christine Pollak, Anand Dhruva, Wendy Hartogensis, Michael Lister, Stephanie W. Cheng, Kavita K. Mishra. Mindfulness-based group medical visits: Strategies to improve equitable access and inclusion for diverse patients in cancer treatment. Journal of Clinical Oncology. 2024. PMID:

Samantha Catherine Fisch, Elene Tsopurashvili, Sai Sahitha Somepalle, Mia Salans, Harish Vasudevan, Amy Jo Chien, Melanie Majure, Hope S. Rugo, Ronald Balassanian, Lauren Boreta, Michelle E. Melisko, Laura Ann Huppert. A single center retrospective cohort study of patients with metastatic breast cancer and leptomeningeal disease: Updated survival data and subgroup analyses by breast cancer subtype. Journal of Clinical Oncology. 2024. PMID:

Walsh K, Manochakian R, Schwartz J, Brondfield S. Launching an International Community of Practice in Hematology/Oncology Medical Education. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2024. PMID: 38776483

Marcello Rotta, Yasmin Abaza, Hetty E Carraway, Bradley W. Christensen, Mitul Gandhi, Paul B. Koller, Ayman H. Qasrawi, Gary J. Schiller, Catherine Choy Smith, Uzma Ahmed, Alexandru Cacovean, Nicole Kowalczyk, Stephan W. Morris, Mona Vimal, Sauji Yachamaneni, Thomas Butler, Eunice S. Wang, Farhad Ravandi-Kashani. Covalent-103: A phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL). Journal of Clinical Oncology. 2024. PMID:

Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 38862008

Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO precision oncology. 2024. PMID: 38865673

Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nature medicine. 2024. PMID: 38824244

Ponce RKM, Luck C, Okimoto RA. Molecular and therapeutic advancements in Capicua (CIC)-rearranged sarcoma. Frontiers in cell and developmental biology. 2024. PMID: 38882060

Owen DH, Ismaila N, Freeman-Daily J, Roof L, Singh N, Velazquez AI, Leighl NB. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. PMID: 38815183

Alex Chehrazi-Raffle, Michael Olufemi Shodiya, Edward Maldonado, Tamer Othman, Hedyeh Ebrahimi, Regina Barragán Carrillo, Xiaochen Li, Adam Rock, Abhishek Tripathi, Sumanta Kumar Pal, Tanya B. Dorff, Ali Zhumkhawala, Rasmus Hoeg, Caspian Oliai, Rebecca L. Olin, Matthew Genyeh Mei. Multicenter analysis of high-dose chemotherapy (HDCT) regimens for the treatment of patients (pts) with recurrent germ cell tumors (GCTs). Journal of Clinical Oncology. 2024. PMID:

Turja Chakrabarti, Greg M. Allen, Matthew A. Gubens, Claire Mulvey, Ana I. Velazquez Manana, Wei Wu, Megan Gee, Lisa Tan, Trever G. Bivona, Collin M. Blakely. A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer. Journal of Clinical Oncology. 2024. PMID:

Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. PMID: 38805668

Azad TD, Nanjo S, Jin MC, Chabon JJ, Kurtz DM, Chaudhuri AA, Connolly ID, Hui AB, Liu CL, Merriott D, Ko R, Yoo C, Carter J, Chen E, Bonilla R, Hata A, Katakami N, Irie K, Yano S, Okimoto R, Bivona TG, Newman AM, Iv M, Nagpal S, Gephart MH, Alizadeh AA, Diehn M. Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis. NPJ precision oncology. 2024. PMID: 38806586

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, Bajpai J, Barrios CH, Bergh J, Bergsten-Nordström E, Biganzoli L, Cardoso MJ, Carey LA, Mac Gregor MC, Chidebe R, Cortés J, Curigliano G, Dent RA, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Franco Millan SX, Gilchrist J, Gligorov J, Gradishar WJ, Haidinger R, Harbeck N, Hu X, Kaur R, Kiely B, Kim SB, Koppikar S, Kuper-Hommel MJJ, Lecouvet FE, Mason G, Mertz SA, Mueller V, Myerson C, Neciosup S, Offersen BV, Ohno S, Pagani O, Partridge AH, Penault-Llorca F, Prat A, Rugo HS, Senkus E, Sledge GW, Swain SM, Thomssen C, Vorobiof DA, Vuylsteke P, Wiseman T, Xu B, Costa A, Norton L, Winer EP. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast (Edinburgh, Scotland). 2024. PMID: 38896983

Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. Annals of surgical oncology. 2024. PMID: 38797790